Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Agricultural and Food Chemistry|December 22, 1999
Emulsifying properties of acidic subunits of soy 11S globulinM Liu, D S Lee, S Damodaran
The American Journal of Psychiatry|April 1, 1992
Prospective study of neuroleptic-induced dystonia in mania and schizophreniaR Khanna, A Das, S S Damodaran
Psychopathology|January 1, 1995
Trichotillomania: symptom or syndrome? A need for revisionS S Damodaran, K T Jayalekshmi, R Khanna
Biochemistry|July 12, 1994
Isolation and characterization of titin T1 from bovine cardiac muscleK M Pan, S Damodaran, M L Greaser
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|February 4, 2010
Experience of clomiphene use in a district general hospitalS Damodaran, L Mamatha, M Pheely, et al.
Indian Journal of Psychiatry|July 12, 2011
Multifocal leucoencephalopathy presenting as antidepressant induced maniaS S Damodaran, V K Sinha, A Das, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2S Damodaran, C C O'Sullivan, A Elkhanany, et al.
Clinical and Experimental Dermatology|October 4, 2018
Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skinJ S Lehman, S Dasari, S S Damodaran, et al.
ESMO Open|February 5, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterationsS A Piha-Paul, C Tseng, H T Tran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialM P Goetz, N A Bagegni, G Batist, et al.
Pageof 3